SK bioscience – Weekly Recap
SK bioscience is a South Korean vaccine developer that continued to expand its global footprint this week, with developments spanning new product licensing, multilateral tenders, and international partnerships. This weekly summary reviews the company’s key moves and assesses their implications for its long-term growth trajectory.
The most notable update was SK bioscience’s licensing agreement with the U.S. Centers for Disease Control and Prevention for an injectable inactivated rotavirus vaccine, marking the first time a Korean company has obtained vaccine technology from the CDC. The program, co-funded with the RIGHT Foundation, targets low- and middle-income countries where rotavirus mortality remains high and demand is shifting toward injectable options.
SK bioscience has begun process development in Korea with plans to enhance efficacy and reduce production costs before entering clinical trials and regulatory review. If successfully developed and approved, the candidate could tap into a rotavirus vaccine market projected to grow from $8.12 billion in 2024 to $13.9 billion by 2033, supported by rising UNICEF procurement volumes in Gavi-supported countries.
The company also achieved its first UNICEF procurement contract for its cell culture-based influenza vaccine SKYCellflu, covering both Southern and Northern Hemisphere programs in 2026. Under this deal, SK bioscience will supply about 640,000 doses to markets including Laos, Myanmar, Fiji, Ethiopia, Lebanon, Albania, and Palestine, becoming UNICEF’s sole Southern Hemisphere supplier and a key Northern Hemisphere provider.
This UNICEF agreement complements SK bioscience’s existing relationship with the Pan American Health Organization and enables more consistent year-round utilization of its influenza manufacturing lines. While public-sector pricing may constrain margins, the contract strengthens the company’s access to recurring global tenders and institutional revenue streams, enhancing its positioning as a reliable supplier in health emergencies.
In Latin America, SK bioscience advanced its regional “glocalization” strategy via a technology transfer agreement with Colombian state-owned VECOL S.A., initially focused on its WHO-prequalified varicella vaccine SKYVaricella. This partnership supports Colombia’s broader vaccine localization plan and follows SK bioscience’s PAHO varicella tender win and extension through 2027, embedding the firm more deeply in local supply chains.
The Colombian initiative is expected to bolster supply-chain resilience and open additional regional procurement opportunities, with future revenue impact dependent on site build-out and production ramp-up. Combined with SKYCellflu’s WHO Prequalification and demonstrated Phase 3 and real-world effectiveness, these moves strengthen SK bioscience’s appeal in multilateral markets and pandemic response scenarios.
Domestically, the company highlighted its new Songdo headquarters and R&D center through a Family Day event involving more than 450 employees and family members, emphasizing a people-first culture and modern lab infrastructure. Investment in employee engagement and research capacity is intended to support talent retention and long-term innovation productivity, aligning with its expanding global ambitions.
Overall, the week underscored SK bioscience’s strategic focus on institutional demand, emerging-market growth, and localized manufacturing partnerships. These developments collectively enhance its prospects as a competitive global vaccine supplier, particularly in multilateral and low- to middle-income country markets.


